<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202380</url>
  </required_header>
  <id_info>
    <org_study_id>A-PROM</org_study_id>
    <nct_id>NCT04202380</nct_id>
  </id_info>
  <brief_title>Azithromycin for Preterm Pre-labor Rupture of Membranes</brief_title>
  <official_title>Different Azithromycin Protocols for Management of Preterm Pre-labor Rupture of Membranes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The preterm prelabour rupture of membranes is defined as the spontaneous rupture of the fetal
      membranes before 37 completed weeks. Preterm prelabour rupture of membranes complicates up to
      3% of pregnancies and is associated with 30-40% of preterm births. preterm prelabour rupture
      of membranes can result in significant neonatal morbidity and mortality, primarily from
      prematurity, sepsis, cord prolapse, and pulmonary hypoplasia. In addition, there are risks
      associated with chorioamnionitis and placental abruption The diagnosis of spontaneous rupture
      of the membranes is made by maternal history followed by a sterile speculum examination. If
      on speculum examination, no amniotic fluid is observed, clinicians should consider performing
      an insulin-like growth factor-binding protein-1 or placental alpha microglobulin-1 test of
      vaginal fluid to guide further management.

      One of the risks associated with preterm prelabour rupture of membranes is ascending
      infection leading to chorioamnionitis, and subsequent fetal and neonatal infection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days from diagnosis of preterm pre-labor rupture of membranes to delivery.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Preterm Pre-labor Rupture of Membranes</condition>
  <arm_group>
    <arm_group_label>Azithromycin 1 day group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive Azithromycin 1000mg once orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin 5 days group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Patients will receive Azithromycin orally 1000 mg</description>
    <arm_group_label>Azithromycin 1 day group</arm_group_label>
    <arm_group_label>Azithromycin 5 days group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin</intervention_name>
    <description>All patients will receive Ampicillin 2gm IV every 6 hours for 2 days</description>
    <arm_group_label>Azithromycin 1 day group</arm_group_label>
    <arm_group_label>Azithromycin 5 days group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin 500 mg orally once</description>
    <arm_group_label>Azithromycin 5 days group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin 250 mg orally daily for 4 days</description>
    <arm_group_label>Azithromycin 5 days group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gestational age is between 28 wks and 37wks

          2. Singleton living pregnancy.

          3. Confirmed Premature Pre-labor rupture of membranes (PPROM).

        Exclusion Criteria:

          1. previable rupture of membranes (&lt;23+6wks)

          2. Multiple gestations

          3. Macrolide allergy

          4. patient receiving combination macrolide therapy

          5. lethal fetal anomalies

          6. contraindications to expectant management of PPROM at time of diagnosis e.g.
             concurrent preterm labor, placental abruption, chorioamnionitis or non-reassuring
             fetal testing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

